GlassScriptPhysician profile
Samuel E Garcia
NPI 1750662201
$6,923.87
in general payments reported to CMS, 2019-2025
34 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $293 · 2021: $107 · 2022: $718 · 2023: $1,680 · 2024: $1,736 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,741.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.76 | 2023-2025 | |
| Novo Nordisk INC | $940.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $597.02 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Daiichi Sankyo INC. | $531.36 | 2019-2025 | Injectafer |
| Gilead Sciences, INC. | $388.37 | 2020-2025 | Sunlenca, Yeztugo |
| Amgen INC. | $350.16 | 2023-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.91 | 2022-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $327.34 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.82 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $235.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $202.43 | 2019 | |
| Medtronic, INC. | $139.20 | 2023 | Venaseal |
| Bayer Healthcare Pharmaceuticals INC. | $135.00 | 2022-2025 | |
| Pfizer INC. | $109.51 | 2023-2025 | |
| Viiv Healthcare Company | $106.77 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $103.19 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Merck Sharp & Dohme LLC | $94.14 | 2019-2024 | Dificid, Pifeltro, Delstrigo |
| Sanofi Pasteur INC. | $87.69 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.64 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $74.18 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $68.58 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $65.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.79 | 2022 | |
| Agios Pharmaceuticals, INC. | $62.97 | 2024-2025 | Pyrukynd |
| Tandem Diabetes Care, INC. | $55.12 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $41.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $40.89 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $24.93 | 2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $24.04 | 2024 | Krazati |
| Kyowa Kirin, INC. | $21.22 | 2024 | |
| Abbott Laboratories | $18.73 | 2024 | Proclaim |
| Philips North America LLC | $15.03 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.81 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.